TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05490017
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo which is KP104 vehicle containing sodium phosphate, sodium chloride, and L-Lysine Hydrochloride (L-Lys-HCL).
Study: NCT00769886
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop of vehicle in study eye at visit 3 and visit 4.
Study: NCT00230399
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00230399
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00851357
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nicotine patch
Study: NCT01288755
Drug: TMC278
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 25 mg tablet, once daily, for 11 days (TrtA and C)
Study: NCT02600520
Drug: SRP with placebo gel LDD
Approvals — FDA: no, EMA: no, PMDA: no
Description: After SRP, placebo gel was delivered subgingivally into the pocket
Study: NCT03567369
Drug: Traumeel S
Normalized name: Traumeel S Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traummel S 2,2 mg/mL
Study: NCT03053388
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric Oxide given via inhalation in cycles
Study: NCT02038868
Drug: ASP4901
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02038868
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00396513
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00396513
Drug: Simvastatin and Metformin
Normalized name: simvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01389076
Drug: Low Dose Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate is an antifolate drug. It interferes with cells' ability to copy their DNA. This mainly affects cells that are dividing frequently, such as immune system cells and cancer cells. Methotrexate will be used in this study to try to prevent the occurrence of HAMA by limiting your body's ability to produce anti mouse antibodies.
Study: NCT00003899
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01517932
Drug: saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this arm,midazolam(0.03-0.05mg/kg), propofol(1.5-2.5mg/kg),sufentanil(0.6-0.82μg/kg )and rocuronium(0.8-1.0mg/kg) were used in anesthesia induction.~Anaesthesia was maintained with propofol（4-6mg kg-1h-1），remifentanil (0.1-0.2 μg kg-1 min-1）and sevoflurane（1%).Propofol was titrated to maintain intraoperative Narcotrend values between 20 and 46.~Patients in this arm received saline placebo of the same volume i.v. during 10 minutes 1 hour before the end of surgery
Study: NCT00547274
Drug: MK0767
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00434681
Drug: paracetamol 4.8% paediatric oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00900510
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04139629
Drug: treatment of infertility with ART
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: COS in gonadotropin-releasing hormone (GnRH) antagonist protocol with IVF/ICSI, fresh ET and, if no pregnancy occurred, frozen/thawed ET (for all embryos resulting from this COS) will be performed.
Study: NCT02998931
Drug: Glutamin
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteral Glutamine 0.3g/kg/day powdered glutamine to be mixed in with water and given via nasogastric tube q4 hrs
Study: NCT02712008
Drug: REGN910-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-formulation for intravitreal (IVT) injection consisting of REGN910 (nesvacumab) and REGN3 (aflibercept)
Study: NCT00496015
Drug: Paracetamol.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body weight of \< 7 kg: none; Body weight of ≥ 7 kg to \< 9 kg : 3 suppositories of 125 mg to be administered at 8h intervals after vaccination. Body weight of ≥ 9 kg: 4 suppositories of 125 mg to be administered at 6h intervals after vaccination.
Study: NCT01590979
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: two times a day, 12 hour intervals
Study: NCT00138749
Drug: SS-RBX
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01865266
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01153165
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the control group will receive a matched placebo. At week 4 participants will be assessed for response to treatment. If no response, dose of placebo will be increased to 40mgs for the remaining 8 weeks of the study. Patients who respond will remain on 20mgs for remaining 8 weeks.
Study: NCT00276510
Drug: EGb 761® (Tanakan®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg, 1 tablet twice a day, oral route, during 5 years.
Study: NCT02210000
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camicinal matching placebo is available as tablet to be taken orally with 100mL of water in the morning
Study: NCT01199198
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo by mouth once a day for 14 days.
Study: NCT04668365
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, disease progression after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
Study: NCT02123134
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate buffered saline placebo for injection
Study: NCT01776658
Drug: SYL1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocular topical administration of SYL1001 for 10 consecutive days
Study: NCT01776658
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocular topical administration of placebo for 10 consecutive days
Study: NCT04125563
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft gel capsules filled with placebo - sorbitol and colorant.
Study: NCT01227798
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline
Study: NCT04120350
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol
Study: NCT00883779
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: po on days 15-28 of each 4 week cycle until disease progression
Study: NCT01191723
Drug: MAP0004
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0mg orally inhaled MAP0004 administered in Treatment B as per protocol
Study: NCT01191723
Drug: Inhaler Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Inhaler administered in Treatments A and C
Study: NCT01191723
Drug: Placebo Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Moxifloxacin administered in Treatment B and Treatment C
Study: NCT01885156
Drug: Naftin 1% Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topically applied once a day
Study: NCT01885156
Drug: Placebo Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topically applied once a day
Study: NCT03226717
Drug: Antiviral agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination therapy consists of Sofosbuvir,daclatasvir and ribavirin
Study: NCT02972060
Drug: ADT
Normalized name: Radtue
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADT by means of LHRH antagonist for 24 weeks or by LHRH agonist therapy for 24 weeks with 4 weeks of anti-androgen to prevent flare.~This includes leuprolide, goserelin, triptorelin, and degarelix. Beyond week 24, the treatment will be left to the discretion of the treating physician.
Study: NCT02091817
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given to control group and experimental group as well.
Study: NCT01918124
Drug: Cisplatin and Doxorubicin and Cyclophosphamide
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Four courses of cisplatin (50mg/m2) and doxorubicin (60mg/m2) and cyclophosphamide (600mg/m2) chemotherapy given at 3 week intervals following completion of radiotherapy.
Study: NCT01957215
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical indomethacin
Study: NCT01670825
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid and local anesthetic injection plus sham pulsed radiofrequency over each affected occipital nerve
Study: NCT00150514
Drug: Oralgen
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04129619
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT02631096
Drug: ARB-001467
Normalized name: revakinagene taroretcel
Approvals — FDA: no, EMA: no, PMDA: no
Description: An IV infusion of ARB-001467
Study: NCT01685060
Drug: LDK378
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceritinib/LDK378 was supplied as 150 mg hard gelatin capsules and were administered orally, once-daily at a dose of 750 mg on a continuous dosing schedule (5 x 150 mg capsules).
Study: NCT00547989
Drug: standard anaesthesia (bupivacaine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration with bupivacaine and Piritramide and Paracetamol as postoperative analgesic, and ondansetron as required
Study: NCT01091675
Drug: Etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 90 mg/day/PO during 4 weeks Positive response to the therapy (in investigator opinion): Ongoing treatment with 90 mg/day/PO until 24 weeks.
Study: NCT02038790
Drug: Zubsolv sublingual tablets
Normalized name: Zubsolv Sublingual Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single Zubsolv sublingual tablet containing 5.7mg buprenorphine and 1.4mg naloxone taken sublingually on either Day 0 or Day 1, depending on randomized treatment arm assignment. Study drug will be administered by designated qualified study personnel at the site in the morning prior to 9:00 a.m. under fasting conditions.
Study: NCT02941042
Drug: NNC9204-1177
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose administered subcutaneously ( s.c. under the skin)
Study: NCT02941042
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose administered subcutaneously ( s.c. under the skin)
Study: NCT00948194
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhalation - 40 ppm, at the initiation of anesthesia to the end of surgery
Study: NCT01821573
Drug: injection of NaCl 0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator group: injection of NaCl 0.9%:~* 3 ml of NaCl 0.9% in rectus femoris in 3 points~* 1.4 ml of NaCl 0.9% in medial gastrocnemius in 1 point~* 1.4 ml of Nacl 0.9% in lateral gastrocnemius in 1 point~* 1.2 ml of NaCl 0.9% in soleus in 3 points
Study: NCT00002805
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002805
Drug: therapeutic hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03603327
Drug: Direct acting anti-viral agents
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care for Hepatitis C treatment
Study: NCT02253927
Drug: BILR 355 - D1
Normalized name: PHOSPHOLIPASE D1
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02253927
Drug: BILR 355 - D3
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02203175
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: before the anesthesia induction 50 mcgr fentanyl
Study: NCT04148872
Drug: Chemodenervation (4 months)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A neurotoxin that temporarily reduces muscle activity and minimizes the effects of uncoordinated muscle.
Study: NCT03875872
Drug: inhalation anaesthetics
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who had surgeries and were anaesthetized via inhalation at Queen Mary Hospital, Hong Kong from Jan 2015 to Dec 2017
Study: NCT00348712
Drug: inhaled human insulin
Normalized name: insulin, regular, human Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treat-to-target dose titration scheme, inhalation.
Study: NCT02647307
Drug: DS-1040b
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 12-hour intravenous infusion of DS-1040b (20 mg)
Study: NCT02259764
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00784459
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with Placebo, IV
Study: NCT03324776
Drug: Afrezza Inhalant Product
Normalized name: Afrezza Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mealtime Ultra-Rapid Acting Insulin
Study: NCT00960063
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00960063
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04363203
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin: 2x250mg by mouth (PO) in the AM on Day 1, followed by 250mg PO every day on Days 2-5.
Study: NCT02737605
Drug: Oral Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo orally.
Study: NCT02737605
Drug: Intranasal Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive intranasal placebo (1 spray in each nostril at 0, 5, and 10 minutes).
Study: NCT04258761
Drug: 10XB-101 Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active test article
Study: NCT04363203
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in pill packs identical to study drugs
Study: NCT03561675
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
Study: NCT01847352
Drug: Intravenous administration of ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous administration of ferric carboxymaltose 15mg/kg up to a maximum dose of 1000mg
Study: NCT01222845
Drug: Test meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Porridge made from rolled, or pinhead oats providing 50 g of carbohydrate
Study: NCT00424099
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule, orally every two hours as needed up to a maximum of 4 capsules per day for a period of 14 days.
Study: NCT02570503
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ketorolac (30mg/ml)- 1 ml
Study: NCT02570503
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: epinephrine (1mg/ml)-1ml
Study: NCT03008889
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will start with taking 900mg of the placebo once per day for one week (study days 1-7). At Day 7, parents (or primary caregiver) and subjects will return to the study site to review adverse events. The dosing for the placebo will increase in the same fashion as the active treatment.~In the absence of dose limiting adverse events attributable to the study drug, the dose will be gradually increased to 900 mg twice per day for study days 8-28.~If this dose is well-tolerated, the dose will be increased to 900 three times per day for study days 29-63.
Study: NCT03319797
Drug: NOVOCART® Inject plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with NOVOCART® Inject plus (Autologous chondrocyte implantation)
Study: NCT03833661
Drug: M7824
Normalized name: M7824
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received an intravenous infusion of 1200 milligrams (mg) M7824 once every 2 weeks until confirmed disease progression, death, unacceptable toxicity or study withdrawal.
Study: NCT04239586
Drug: Sulfonylurea
Normalized name: Sulfonylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting treatment with sulfonylurea class of drug
Study: NCT00255983
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets BID for 5 days
Study: NCT02296905
Drug: ABT-493
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 2 single doses of ABT-493 will be given orally in combination with ABT-530.
Study: NCT02296905
Drug: ABT-530
Normalized name: ABT-925
DrugBank: ABT-560 (DB06093)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 3 single doses of ABT-530 will be given orally alone or in combination with ABT-493.
Study: NCT00142285
Drug: Zinc sulphate (20 mg)
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03702647
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mL of normal saline placed in the POEM tunnel
Study: NCT04086966
Drug: [68Ga]PSMA-PET/MRI or PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[68Ga\]PSMA-PET/MRI or PET/CT
Study: NCT01699152
Drug: TG02 citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG02 citrate capsules
Study: NCT03993704
Drug: LHF-535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral suspension administered once daily for 14 days
Study: NCT00854061
Drug: T-Pred
Approvals — FDA: no, EMA: no, PMDA: no
Description: sterile ophthalmic solution
Study: NCT00780104
Drug: Rapamycin + MEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapamycin loading dose of 12 mg followed by a single daily dose for 8 days of 4 mg/day + MEC (Mitoxantrone 8 mg/m2/day IV, Etoposide 100 mg/m2/day IV and Cytarabine 1000 mg/m2 IV every 24 hours for 5 days. Starts after 4th dose of sirolimus.
Study: NCT01278394
Drug: AN2690 Solution, 5.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily application for 360 days
Study: NCT00857649
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablets Once Daily
Study: NCT02974660
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03975049
Drug: FOLFOXIRI Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 85 mg/m2 on day 1; irinotecan 150 mg/m2 on day 1; leucovorin 400 mg/m2 on day 1; fluorouracil 2400 mg/m2 civ over 46h; treatment will be repeated every 14 days; prophylactic G-CSF support is recommended.
Study: NCT03975049
Drug: Folfox Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 85 mg/m2 on day 1; leucovorin 400 mg/m2 on day 1; fluorouracil 400 mg/m2 bolus and 2400 mg/m2 civ over 46h; treatment will be repeated every 14 days.
Study: NCT00581854
Drug: modified Hyper-CVAD
Normalized name: Hyper-Sal
Approvals — FDA: no, EMA: no, PMDA: no
Description: rituximab and modified hyperfractionated cyclophosphamide, vincristine doxorubicin, dexamethasone (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab maintenance therapy consisting of four weekly doses every six months for two years
Study: NCT01378676
Drug: Placebo (Part B)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets once daily for 14 days (Part B)
Study: NCT02049294
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02158091
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous chemotherapy
Study: NCT00220272
Drug: SR57667B
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03494270
Drug: Rosuvamibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10mg/Ezetimibe 10mg
Study: NCT03494270
Drug: Monorova
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 20mg
Study: NCT01336933
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00085163
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00085163
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00085163
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00293657
Drug: Lornoxicam 8 mg
Normalized name: lornoxicam 8 MG
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00293657
Drug: Lornoxicam 16 mg
Normalized name: Lornoxicam 16 mg prolonged-release oral tablet
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00293657
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00788307
Drug: liothyronine sodium
Normalized name: Liothyronine Sodium
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03917797
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone; Cyclophosphamide; Prednisone; Mycophenolate
Study: NCT03917797
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSC infusion vehicle
Study: NCT03324490
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Neuro-axially injected
Study: NCT01366001
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual administration, Placebo administered once daily for 10 consecutive days.
Study: NCT01239511
Drug: green tea polyphenols (STA-2)
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules t.i.d., after meal
Study: NCT01677689
Drug: Apomivir®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study Group: Apomivir® 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal.